EUVIMEDScopri EUVIMED
StudienprotokollOpen access

Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study

Zhiqiang Gao iD, Jiajun Teng iD, Rong Qiao iD, Jialin Qian iD, Feng Pan iD, Meili Ma iD, Jun Lu iD, Bo Zhang iD, Tianqing Chu iD, Hua Zhong iD

JMIR Research Protocols · 2024

DOI: 10.2196/64950 ↗

At a glance

Studienprotokoll in JMIR Research Protocols, 2024. Written by Zhiqiang Gao and 9 co-authors. Institution: Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Cryosurgery, Lung Neoplasms. Cited 3 times so far (Crossref); 27 references. The full text is freely available in PubMed Central.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical.

Objective

This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC.

Methods

This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded.

Results

The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027.

Conclusions

This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. Trial Registration ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 International Registered Report Identifier (IRRID) PRR1-10.2196/64950

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCryosurgeryLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyPilot ProjectsTreatment OutcomeClinical Trials, Phase II as Topic

Author keywords

cryoablationimmunotherapynonsquamous non–small cell lung cancer

Substances

Antibodies, Monoclonal, Humanizedsintilimab

Authors and institutions

  • Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID profiles: Zhiqiang Gao, Jiajun Teng, Rong Qiao, Jialin Qian, Feng Pan, Meili Ma, Jun Lu, Bo Zhang, Tianqing Chu, Hua Zhong

Cite

APA

Gao, Z., Teng, J., Qiao, R., Qian, J., Pan, F., Ma, M., Lu, J., Zhang, B., Chu, T., & Zhong, H. (2024). Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study. JMIR Research Protocols. https://doi.org/10.2196/64950

Vancouver

Gao Z, Teng J, Qiao R, Qian J, Pan F, Ma M, et al. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study. JMIR Research Protocols. 2024. doi:10.2196/64950

BibTeX
@article{Gao2024,
  author = {Gao, Zhiqiang and Teng, Jiajun and Qiao, Rong and Qian, Jialin and Pan, Feng and Ma, Meili and Lu, Jun and Zhang, Bo and Chu, Tianqing and Zhong, Hua},
  title = {Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study},
  journal = {JMIR Research Protocols},
  year = {2024},
  doi = {10.2196/64950}
}
Start for free →